December 22, 2021 -- Novavax announced that the European Commission (EC) has granted the company a conditional marketing authorization (CMA) for its Nuvaxovid COVID-19 vaccine for use in individuals age 18 and older. The CMA applicable in all 27 European Union member states.
According to the company, in two phase 3 clinical trials, NVX-CoV2373, Novavax's COVID-19 vaccine candidate, demonstrated high efficacy and an acceptable safety and tolerability profile. Novavax and the EC announced an advance purchase agreement in August 2021 in which the EC would purchase up to 200 million doses. The vaccine is also currently under review by multiple regulatory agencies worldwide.